Clinical and immunological mechanisms of myasthenia gravis and pregnancy
10.3760/cma.j.cn113694-20220628-00509
- VernacularTitle:重症肌无力与妊娠的临床与免疫机制研究现状
- Author:
Xiaoqing LIU
1
;
Manqiqige SU
;
Sushan LUO
;
Chongbo ZHAO
;
Yali ZHANG
Author Information
1. 内蒙古医科大学赤峰临床医学院，赤峰 024000
- Keywords:
Myasthenia gravis;
Pregnancy;
Myasthenia gravis, neonatal;
Hypothalamic-pituitary-endocrine axis;
Antibodies
- From:
Chinese Journal of Neurology
2023;56(3):338-343
- CountryChina
- Language:Chinese
-
Abstract:
The clinical symptoms of myasthenia gravis (MG) in women are closely related to pregnancy, and the outcome of pregnancy and neonates is related to MG disease control, comorbidities and antibody types. The exacerbation of muscle weakness usually appeared in the first trimester and postpartum 0-3 months. The adverse pregnancy outcomes of MG mothers are mainly fetal arrest and abortion. Neonatal muscle weakness and congenital joint flexion are common neuromuscular lesions in childbirth. During pregnancy, the immune system of MG pregnant women is regulated by estrogen/progesterone/prolactin/glucocorticoid, and the main result is to inhibit pro-inflammatory response and promote immune tolerance. However, the specific interaction between MG and pregnancy remains to be elucidated in prospective cohort studies.
